<description>&lt;p&gt;Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo). &lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;References: &lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/41626799/"&gt;&lt;u&gt;https://pubmed.ncbi.nlm.nih.gov/41626799/&lt;/u&gt;&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://www.ncbi.nlm.nih.gov/books/NBK548187/"&gt;&lt;u&gt;https://www.ncbi.nlm.nih.gov/books/NBK548187/&lt;/u&gt;&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/41626799/"&gt;&lt;u&gt;https://pubmed.ncbi.nlm.nih.gov/41626799/&lt;/u&gt;&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;
</description>

Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo). References: <a href="https://pubmed.ncbi.nlm.nih.gov/41626799/">https://pubmed.ncbi.nlm.nih.gov/41626799/</a><a href="https://www.ncbi.nlm.nih.gov/books/NBK548187/">https://www.ncbi.nlm.nih.gov/books/NBK548187/</a><a href="https://pubmed.ncbi.nlm.nih.gov/41626799/">https://pubmed.ncbi.nlm.nih.gov/41626799/</a>

PsychRounds: The Psychiatry Podcast

VMAT2 Inhibitors: Valbenazine (Ingrezza) and Deutetrabenazine (Austedo)

VMAT2 Inhibitors: Valbenazine (Ingrezza) and Deutetrabenazine (Austedo)

Description